NewAmsterdam Cash And Short Term Investments from 2010 to 2024
| NAMS Stock | 25.86 0.37 1.41% |
Cash And Short Term Investments | First Reported 2010-12-31 | Previous Quarter 340.4 M | Current Value 231 M | Quarterly Volatility 140.7 M |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 75.5, Dividend Yield of 0.0 or PTB Ratio of 3.34. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Cash And Short Term Investments |
Latest NewAmsterdam Pharma's Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of NewAmsterdam Pharma over the last few years. Short Term Investments is an account in the current assets section of NewAmsterdam Pharma balance sheet. This account contains NewAmsterdam Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by NewAmsterdam Pharma fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. NewAmsterdam Pharma's Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
NewAmsterdam Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 76,634,292 | |
| Geometric Mean | 18,801,544 | |
| Coefficient Of Variation | 183.54 | |
| Mean Deviation | 104,006,467 | |
| Median | 7,861,000 | |
| Standard Deviation | 140,652,944 | |
| Sample Variance | 19783.3T | |
| Range | 430.7M | |
| R-Value | 0.67 | |
| Mean Square Error | 11769.1T | |
| R-Squared | 0.45 | |
| Significance | 0.01 | |
| Slope | 21,041,399 | |
| Total Sum of Squares | 276965.5T |
NewAmsterdam Cash And Short Term Investments History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Cash And Short Term Investments, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 340.4 M | 231 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.